Amanote Research

Amanote Research

    RegisterSign In

Ocrelizumab for Relapsing or Primary Progressive MS

Prescriber - United Kingdom
doi 10.1002/psb.1705
Full Text
Open PDF
Abstract

Available in full text

Categories
Pharmacology
Date

September 1, 2018

Authors
Steve Chaplin
Publisher

Wiley


Related search

Endocarditis Following Ocrelizumab in Relapsing-Remitting MS

Neurology: Neuroimmunology and NeuroInflammation
Neurology
2020English

Ocrelizumab in the Treatment of Primary-Progressive Multiple Sclerosis

Medical Council
2018English

Lymphopenia and DMTs for Relapsing Forms of MS

Neurology: Clinical Practice
Neurology
2019English

Reduced Rich-Club Connectivity Is Related to Disability in Primary Progressive MS

Neurology: Neuroimmunology and NeuroInflammation
Neurology
2017English

Natalizumab for Relapsing-Remitting Ms in the Uk Top Cohort

Journal of Neurology, Neurosurgery and Psychiatry
PsychiatryMental HealthNeurologySurgery
2014English

Progressive Multifocal Leukoencephalopathy and Relapsing-Remitting Multiple Sclerosis

Archives of Neurology
2009English

Siponimod Chips Away at Progressive MS

Cell
BiochemistryGeneticsMolecular Biology
2019English

Lymphopenia and DMTs for Relapsing Forms of MS: Considerations for the Treating Neurologist

Neurology: Clinical Practice
Neurology
2019English

Extensive White Matter Lesions After 2 Years of Fingolimod: Progressive Multifocal Leukoencephalopathy or MS Relapse?

Multiple Sclerosis
Neurology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy